

21 July 2023

## **Dropsuite Limited (DSE)**

## **Keeping the faith**

Following another solid quarter, we remain favourably disposed to DSE's strategic intent within a high growth and global market. Reiterate Buy with new \$0.31ps TP.

#### 2Q23 broadly in line with expectations

- DSE reported a reasonably solid 2Q23 result, with the key feature being the ARR of A\$30.4m, +8% on pcp in AUD terms and +9% on pcp in USD terms. On a yearon-year basis, DSE is growing at ~2x system growth.
- The ARR growth was predicated on continued growth in both ARPU (+2% on pcp in AUD terms) and net users (+6% on pcp), with the latter being achieved despite the deactivation of a major legacy hosting partner.
- Consistent with management's expectations, DSE's GP margin stayed within its target range at 69% (and was above our 68% estimate), while Op. CF continued to be positive at \$0.34m, down from \$0.40m in pcp.

#### Positive outlook commentary remains intact

- Notwithstanding a more modest quarter of growth and the recent launch of Microsoft's Syntex (which is an Alpowered tool that incl. a backup solution for Microsoft 365), DSE's strategic intent and outlook are unchanged.
- While Syntex is undoubtedly a threat, we believe DSE's

   (i) TAM is large, and growing, and (ii) market leading
   position with MSPs can be retained via its commitment
   to product quality/innovation and independence.

## Modest earnings forecasts revisions

 We have lowered our EPS estimate for both FY23 and FY24 by 1%, with our FY25 estimate unchanged. The key drivers are (i) lower revenues, driven by lower user growth and ARPU, and (ii) higher GP margin.

### Reiterate Buy and lift TP to \$0.31ps (from \$0.29ps)

- We believe DSE has the products, business model and capital to exceed system growth (~25% p.a.) within its target market (data back-up and archiving) over the next several years.
- Given DSE's ability to leverage its strong balance sheet to supplement what we expect to be a strong multi-year organic growth profile with M&A, we reiterate our Buy rating with a new TP of \$0.31ps (previously \$0.29ps).
- While our DCF valuation is unchanged at \$0.29ps, we have transitioned to a valuation blend comprising our DCF valuation and EV/sales valuation of \$0.33ps (using an ascribed FY24 multiple of 5x).
- Consistent with DSE's partner-led business model and growth strategy, the key share price catalysts include (i) continued growth in ARR in excess of reinvestments, (ii) product innovation, and (iii) strategic M&A.

BUY Share Price: A\$0.29

Target Price: A\$0.31

#### **Company Data**

Shares – ordinary (M)	692.7
Dilution (M)	16.8
Total (fully diluted) (M)	709.5
Market capitalisation (\$M)	197.4
12-month low/high (\$)	0.16 - 0.39
Average monthly turnover (\$M)	19.8
GICS Industry	Software

#### Financial Summary (fully diluted/normalised)

Year End December	2021A	2022A	2023F	2024F	2025F
Revenue (A\$m)	11.7	20.7	30.9	41.7	51.7
Costs (A\$m)	11.7	19.4	28.8	38.7	46.1
EBITDA (A\$m)	0.0	1.3	2.1	3.0	5.7
NPAT (A\$m)	0.0	1.5	1.7	2.4	4.4
EPS (¢)	0.0	0.2	0.2	0.3	0.6
EPS Growth (%)	98.7	>100.0	14.5	37.4	84.9
PER (x)	nm	137.3	118.7	85.4	46.2
FCF (A\$m)	0.2	0.9	1.4	1.7	4.3
FCF per share (cps)	0.0	0.1	0.2	0.2	0.6
Price to FCF (x)	912.1	234.3	141.4	115.8	48.0
EV (A\$m)	162.8	177.0	178.5	177.1	175.4
EV/EBITDA	nm	141.5	85.3	59.7	30.8
Payout ratio (%)	0.0	0.0	0.0	0.0	0.0
Dividend (¢)	0.0	0.0	0.0	0.0	0.0
Net Yield (%)	0.0	0.0	0.0	0.0	0.0
Franking (%)	0.0	0.0	0.0	0.0	0.0

#### DSE - performance over one year



#### **Disclosure and Disclaimer**

This report must be read with the disclosure and disclaimer on the final page of this document.

James Lennon +61 2 9239 9618



# **Analysis**

Source: Petra Capital

Market published   Market publ	Dropsuite													
Machine   Mach														
Price surper   Chamber   Price   Pri								12-MONTH SHARE PRICE P	PERFORMA	NCE				
Process part   12	Recommendation						Buy							
March Carlot Bender	Price	A\$						200		——DSE	—xso			Л
March Carlot Bender	Price target (12-month)	A\$					0.31	150 -					~~~	ا <sup>س</sup> م
March Carlot Bender	52 week high / low	A\$				0	0.16 - 0.39					my	ro wy	
Performer pright   Property   P	Market capitalisation	A\$m					197.4	100	-	MARRA			~~~	~~
New File   File   Property   Pr	Shares on issue (basic)	no.					692.7	50	•					
No.   Property   Pro	Performance rights	no.					16.8	50 -						
New Part   Part   No.	Other equity	no.						0						
Mathematical   Math	Shares on issue (diluted)	no.					709.5		Nov-22	Jan-23	Mar-23	Ma	y-23	Jul-23
Properties profet   Profession   Professio									0					
Perpense														
Normalise   PS   Gilluler	Reported net pront	şm	(0.0)	1.5	1.7	2.4	4.4							
Monematical diluted PER	Reported EPS (diluted)	¢	(0.0)	0.2	0.2	0.3	0.6	EBIT	\$m	(0.0)	1.2	2.0	2.9	5.6
Note	Normalised EPS (diluted)	¢	(0.0)	0.2	0.2	0.3	0.6	Net interest	\$m	(0.0)	(0.3)	(0.2)	(0.3)	(0.3)
Adjusted Op CF per share	Growth	%	98.7	>100.0	14.5	37.4	84.9	Non-operating income	\$m	0.0	0.0	0.0	0.0	0.0
Agustratio Co Fine shave	Normalised diluted PER	x	nm	137.3	118.7	85.4	46.2	Pretax Profit	\$m	(0.0)	1.5	2.3	3.2	5.9
Majuration   Fig.   Profice for each flow per share								Tax expense	\$m	0.0	0.0	0.6	8.0	1.5
Price to the count flow year shave   1,	Adjusted Op. CF per share	¢	0.0	0.1	0.2	0.3	0.6	Minorities	\$m	0.0	0.0	0.0	0.0	0.0
Price cash flow yield   W	Adjusted FCF per share	¢	0.0	0.1	0.2	0.2	0.6	Reported NPAT	\$m	(0.0)	1.5	1.7	2.4	4.4
Physical ratio	Price to free cash flow per share	x	912.1	234.3	141.4	115.8	48.0	Significant items	\$m	0.0	0.0	0.0	0.0	0.0
Popurating   No	Free cash flow yield	%	0.1	0.4	0.7	0.9	2.1	Underlying NPAT	\$m	(0.0)	1.5	1.7	2.4	4.4
Popurating   No	Dividend per share	é	0.0	0.0	0.0	0.0	0.0	GROWTH PROFILE		2021A	2022A	2023F	2024F	2025F
Selection   Sele	·								%					
Fembry   F	•													
Enterprise value														
Part	g													
EVEBIT	Enterprise value	\$m	162.8	177.0	178.5	177.1	175.4	· -						
EVEBIT   X	•					59.7			%					
Price to NTA														
Receivable   Rec	Price to book (NAV)	х	8.9	8.1	7.3	6.5	5.4	BALANCE SHEET		2021A	2022A	2023F	2024F	2025F
Method   M	Price to NTA	х	8.9	8.1	7.3	6.5	5.4	Cash	\$m	21.6	22.3	25.1	28.7	35.1
EBITD Marigin								Receivables	\$m	2.2	4.1	6.2	8.3	10.3
EBIT margin	KEY RATIOS		2021A	2022A	2023F	2024F	2025F	Inventory	\$m	0.0	0.0	0.0	0.0	0.0
Underlying net profit margin	EBITDA margin	%	0.0	6.0	6.8	7.1	11.0	Other	\$m	0.2	0.4	0.4	0.4	0.4
Retum on average equity	EBIT margin	%	(0.3)	5.8	6.5	6.9	10.8	Current	\$m	24.0	26.8	31.7	37.4	45.8
Return on average assets	Underlying net profit margin	%	(0.3)	7.0	5.5	5.7	8.6	Prop, plant & equip	\$m	0.0	0.1	0.1	0.1	0.1
Net tangible assets per share	Return on average equity	%	16.1	17.5	17.6	17.2	16.4	Goodwill	\$m	0.0	0.0	0.0	0.0	0.0
Net tangible assets per share	Return on average assets	%	17.0	18.7	18.9	18.8	18.0	Other	\$m	0.1	0.1	0.1	0.1	0.1
Net debt //cash								Non current	\$m	0.1	0.1	0.1	0.2	0.2
Interest cover (EBIT / net interest)	Net tangible assets per share	¢	3.2	3.5	3.9	4.4	5.3	Total assets	\$m	24.1	26.9	31.8	37.6	46.0
Captrophysecological Control of Captrophysecological Captrophysecologi	Net debt /(cash)	\$m	(21.6)	(22.3)	(25.1)	(28.7)	(35.1)	Accounts Payable	\$m	2.0	2.5	3.9	5.2	
Part	Interest cover (EBIT / net interest)	х	n/a	n/a	n/a	n/a	n/a	Borrowings	\$m					
DUPONT ANALYSIS  2021A 2022A 2023F 2024F 2025F Equity \$m 21.9 24.2 27.3 31.5 38.1  Net Profit Margin	Leverage (net debt / EBITDA)		n/a	n/a	n/a	n/a	n/a							
DUPONT ANALYSIS   2021A   2022A   2023F   2024F   2025F   2024F   2025F   2024F   2025F   2024F   2025F   2024F   2022A   2023F   2024F   2025F   2024F   2025F   2024F   2022A   2023F   2024F   2025F   2024F   2025F   2024F   2025F   2024F   2025F   2024F   2022A   2023F   2024F   2025F   2024F   20	Gearing (net debt / net debt plus equity)	%	n/a	n/a	n/a	n/a	n/a	Total liabilities	\$m	2.2	2.7		6.1	7.9
Net Profit Margin	DUDONT ANALYSIS		00044	00004	00005	00045	00055							
Asset Turnover x 1.2 1.1 1.0 0.9 0.8 Shareholder's equity \$m														
Return on Assets	=													
Financial Leverage   x   1.2								Shareholder's equity	\$m	21.9	24.2	27.3	31.5	38.1
CASH FLOW SUMMARY  EBITDA \$m 0.0 1.3 2.1 3.0 5.7 Change in working capital \$m (0.0) (1.4) (0.7) (0.8) (0.8) Net interest \$m 0.0 0.2 0.2 0.3 0.3 Tax paid \$m 0.0 0.0 0.0 (0.1) (0.6) (0.9) S2m S1m S1m S0m S0m S0m S0m S0m S0m S0m S0m S0m S0												=	=	=
CASH FLOW SUMMARY  EBITDA Sm 0.0 1.3 2.1 3.0 5.7  Change in working capital \$m (0.0) (1.4) (0.7) (0.8) (0.8)  Net interest \$m 0.0 0.2 0.2 0.3 0.3  Tax paid \$m 0.0 0.0 (0.1) (0.6) (0.9)  Operating cash flow \$m 0.0 0.0 (0.1) (0.1) (0.1) (0.1)  Sumplified Summary Summary Summary Cash Flow Summary Summary Cash Flow Summary Summary Cash Flow Summary Summary Cash Flow Summary Cash Flow Summary Summary Cash Flow Summary Summary Cash Flow Summary C	=							Snares on issue	m	681.9	689.9	701.9	716.0	723.5
Change in working capital \$m\$ (0.0) (1.4) (0.7) (0.8) (0.8) (0.8) Net interest \$m\$ 0.0 0.2 0.2 0.2 0.3 0.3   \$4m	Notalii oli Equity	70	10.1	17.0	17.0		10.4	CASH FLOW		2021A	2022A	2023F	2024F	2025F
Net interest \$m 0.0 0.2 0.2 0.3 0.3	CASH FLOW SUMMARY								\$m		1.3	2.1	3.0	5.7
Net interest \$m 0.0 0.2 0.2 0.3 0.3	\$5m <sub>]</sub>						,	Change in working capital	\$m	(0.0)	(1.4)	(0.7)	(8.0)	(0.8)
Other   Sm   0.3   0.9   0.0   0.0   0.0							/	Net interest	\$m					
Sumble Cash Flow   Sum   Cas	\$4m -							Tax paid	\$m	0.0	0.0	(0.1)	(0.6)	(0.9)
Capital expenditure \$m (0.1) (								Other	\$m	0.3	0.9	0.0	0.0	0.0
Acquisitions/divestment/other \$m 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	\$2m -				/			Operating cash flow	\$m	0.3	0.9	1.5	1.8	4.4
Investing cash flow								Capital expenditure	\$m	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
Free cash flow \$m 0.2 0.9 1.4 1.7 4.3   Equity \$m 18.9 0.0 1.4 1.8 2.1   Increase / (decrease) in borrowings \$m 0.0 0.0 0.0 0.0 0.0 0.0   Operating Cash Flow Capex Net Investments Financing cash flow \$m 18.9 0.0 1.4 1.8 2.1    Operating Cash Flow Capex Net Investments Financing cash flow \$m 18.9 0.0 1.4 1.8 2.1	\$1m -							Acquisitions/divestment/other	\$m	0.0	0.0	0.0	0.0	0.0
Equity \$m 18.9 0.0 1.4 1.8 2.1 Increase / (decrease) in borrowings \$m 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.								Investing cash flow	\$m	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)
-\$1m \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	\$0m					_		Free cash flow	\$m	0.2	0.9	1.4	1.7	4.3
2021A     2022A     2023F     2024F     2025F     Dividend/other     \$m     0.0     0.0     0.0     0.0     0.0       Operating Cash Flow     Capex     Net Investments     Financing cash flow     \$m     18.9     0.0     1.4     1.8     2.1								Equity	\$m	18.9	0.0	1.4	1.8	2.1
Operating Cash Flow Capex Net Investments Financing cash flow \$m 18.9 0.0 1.4 1.8 2.1						_		Increase / (decrease) in borrowings	\$m	0.0	0.0	0.0	0.0	0.0
Dividends — — Free Cash Flow —— Surplus Cash Flow								Dividend/other	\$m	0.0	0.0	0.0	0.0	0.0
—— Lividerius —— Free Cash Flow —— Surplus Cash Flow Net cash flow \$m 19.1 0.9 2.8 3.6 6.4								Financing cash flow	\$m	18.9	0.0	1.4	1.8	2.1
	Dividends — —	Fre	e Cash Flor	w -	—— Sur	plus Cash	rlow	Net cash flow	\$m	19.1	0.9	2.8	3.6	6.4



Petra Capital

ABN 95 110 952 782 ACN 110 952 782 AFSL 317 944

Level 17, 14 Martin Place, Sydney NSW 2000 Level 5, 1 Collins Street, Melbourne VIC 3000

Director:	George Marias	+61 (0)2 9239 9601	gmarias@petracapital.com.au
Research (Resources):	Brett McKay	+61 (0)2 9239 9605	bmckay@petracapital.com.au
Research (Resources):	Hugh Stackpool	+61 (0)2 9239 9625	hstackpool@petracapital.com.au
Research (Resources):	David Brennan	+61 (0)2 9239 9630	dbrennan@petracapital.com.au
Research (Resources):	Andrew Harrington	+61 (0)2 9239 9614	aharrington@petracapital.com.au
Research (Resources):	Kieran Barratt	+61 (0)2 9239 9610	kbarratt@petracapital.com.au
Research (Resources):	Colin McLelland	+61 (0)2 9239 9639	cmclelland@petracapital.com.au
Research (Industrials):	Liam Cummins	+61 (0)2 9239 9607	lcummins@petracapital.com.au
Research (Industrials):	James Lennon	+61 (0)2 9239 9618	jlennon@petracapital.com.au
Research (Industrials):	Sam Haddad	+61 (0)2 9239 9633	shaddad@petracapital.com.au
Research (Industrials):	Ken Wagner	+61 (0)2 9239 9642	kwagner@petracapital.com.au
Research (Industrials):	Daniel Ireland	+61 (0)2 9239 9647	direland@petracapital.com.au
Research (Industrials):	Mark Yarwood	+61 (0)2 9239 9646	myarwood@petracapital.com.au
Research (Healthcare):	Tanushree Jain	+61 (0)2 9239 9649	tjain@petracapital.com.au
Sales:	Frank Barila	+61 (0)2 9239 9603	fbarila@petracapital.com.au
Sales:	Vincent Pisani	+61 (0)2 9239 9617	vpisani@petracapital.com.au
Sales:	Peter Veldhuizen	+61 (0)2 9239 9609	pveldhuizen@petracapital.com.au
Sales:	Neil Watson	+61 (0)2 9239 9602	nwatson@petracapital.com.au
Sales:	Leigh Gardner	+61 (0)400 740 842	lgardner@petracapital.com.au
Sales:	Vince Barila	+61 (0)2 9239 9627	vbarila@petracapital.com.au
Sales:	Colin Redmond	+61 (0)2 9239 9613	credmond@petracapital.com.au
Sales:	Richard Macphillamy	+61 (0)2 9239 9604	rmacphillamy@petracapital.com.au
Sales:	Paul Doherty	+61 (0)407 194 549	pdoherty@petracapital.com.au
Sales:	Tyrone Lara	+61 (0)2 9239 9608	tlara@petracapital.com.au
Sales:	Vince Musumeci	+61 (0)2 9239 9606	vmusumeci@petracapital.com.au
Sales:	Andrew Richards	+61 (0)2 9239 9638	arichards@petracapital.com.au
Sales:	Rob Dobson	+61 (0)2 9239 9628	rdobson@petracapital.com.au
Sales:	Denise Wong	+61 (0)2 9239 9650	dwong@petracapital.com.au
Corporate (ECM):	Verity Barritt	+61 (0)2 9239 9622	vbarritt@petracapital.com.au
Corporate (ECM):	Maureen Baker	+61 (0)438 571 970	mbaker@petracapital.com.au
Corporate (ECM):	Louise Kissell	+61 (0)2 9239 9645	lkissell@petracapital.com.au
Administration:	Suzanne Graham	+61 (0)2 9239 9624	sgraham@petracapital.com.au
Administration:	Belinda Teichmann	+61 (0)2 9239 9636	bteichmann@petracapital.com.au
Administration:	Joanne Condopoulos	+61 (0)2 9239 9635	jcondopoulos@petracapital.com.au
Administration:	Victoria Smith	+61 (0)2 9239 9616	vsmith@petracapital.com.au
Administration:	Larissa Falvo	+61 (0)2 9239 9611	lfalvo@petracapital.com.au
Administration:	Grace Saxby	+61 (0)2 9239 9621	gsaxby@petracapital.com.au
Legal & Compliance:	Danielle Smith	+61 (0)2 9239 9612	dsmith@petracapital.com.au
Financials:	Tony Christelis	+61 (0)2 9239 9615	tchristelis@petracapital.com.au

#### Disclosure

This document has been prepared in Australia by Petra Capital Pty Ltd which holds an Australian Financial Services License AFSL 317 944. Petra Capital Pty Ltd is an ASX and Chi-X Market Participant. Petra Capital Pty Ltd and its associates, officers, directors, employees and agents, from time to time, may receive brokerage, commissions, fees or other benefits or advantages, hold securities in companies researched by Petra Capital Pty Ltd and may trade in these securities either as principal or agent.

#### Disclaimer

The information or advice contained in this report has been obtained from sources that were accurate at the time of issue, however the information has not been independently verified and as such, Petra Capital Pty Ltd cannot warrant its accuracy or reliability. Persons relying on this information do so at their own risk. To the extent permitted by law, Petra Capital Pty Ltd disclaims all liability or responsibility for any direct or indirect loss or damage (including consequential loss or damage) caused by any error or omission within this report, or by persons relying on the contents of this report.

This report is published by Petra Capital Pty Ltd by way of general information or advice only. This report does not take into account specific investment needs or other considerations that may be pertinent to individual investors. Before making any investment decisions based on this report, parties should consider, with or without an investor adviser, whether any relevant part of this report is appropriate to their financial circumstances and investment objectives. Petra Capital Pty Ltd is a licensed institutional/wholesale stockbroking firm. The report is only intended for institutional and sophisticated clients to whom Petra Capital Pty Ltd has issued the report. Petra Capital Pty Ltd is not licensed to advise retail investors should contact their own stockbroker or financial adviser/planner for advice.

#### Ratings

Information regarding the scope and expertise of our research services, processes for selection for coverage, and the management of conflicts of interest can be found on Petra Capital's website at <a href="http://www.petracapital.com.au/research-disclosures">http://www.petracapital.com.au/research-disclosures</a>. Petra Capital uses the following ratings system and definitions: Buy - Forecast to exerte by more than 5% in 12 months; Hold - Forecast to perform up to 5% above or below the current market price in 12 months, or alternatively, where a share price exceeds Petra Capital's valuation but there is a belief that business growth opportunities or commodity price moves, may result in material valuation and share price upside within 12 months; Sell - Forecast to underperform by more than 5% in 12 months; Speculative Buy - Speculative Investment; Take Profits - Recommend taking short term profits in a stock we remain fundamentally positive on a medium term view; Accept Offer - For a company under takeover where we see the offer as a fair price with low risk of a competing offer; No Rating - No rating at this time.

#### **US Investors**

This material is intended for use in the US only by major US Institutional Investors, as that term is defined by the SEC Rule 15a-6. Transactions with US Institutional Investors and major US Institutional Investors, as those terms are defined by SEC Rule 15a-6, are chaperoned by Global Alliance Securities, LLC, ("Global Alliance"), a SEC-registered broker-dealer and FINRA member (web: www.globalalliancesecurities.com) in accordance with the agreement between Global Alliance and Petra Capital Pty Ltd. The information upon which this material is based was obtained from sources believed to be reliable but has not been independently verified. Therefore, its accuracy is not guaranteed. Additional and supporting information is available upon request. This is not an offer or solicitation of an offer to buy or sell any security or to make any investment. Any opinion or estimate constitutes the preparer's best judgement as of the date of preparation and is subject to change without notice. Petra Capital Pty Ltd or Global Alliance and their associates or affiliates, and their respective officers, directors and employees may buy or sell securities mentioned herein as agent or principal for their own account.

#### Other Internationa

International investors are encouraged to contact their local regulatory authorities to determine whether restrictions apply in buying/selling this investment.